Antigenics Oncophage Retrospective Testing For Potency Is Approval Issue
This article was originally published in Pharmaceutical Approvals Monthly
Approval of Antigenics’ Phase III cancer vaccine Oncophage rests on whether FDA will accept retrospective testing of vaccine used in pivotal trials to support product characterization, the company said.
You may also be interested in...
Cell Genesys’ GVAX prostate cancer vaccine is scheduled to enter Phase III at the end of the second quarter under FDA’s special protocol assessment program.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011